Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial

Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial

<b>Objectives</b>: This study aimed to determine the safety and immunogenicity of a combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). <b>Methods</b>: We conducted a randomized, double-blind, placebo-controlled, phase I trial. Three vaccine st...

Full description

Bibliographic Details
Main Authors: Masoud Solaymani Dodaran, Seyed Reza Banihashemi, Ali Es-haghi, Mohammad Hossein Fallah Mehrabadi, Mojtaba Nofeli, Ali Rezaei Mokarram, Ladan Mokhberalsafa, Fariba Sadeghi, Alireza Ranjbar, Akram Ansarifar, Arash Mohazzab, Seyed Amin Setarehdan, Fahimeh Bagheri Amiri, Vahideh Mohseni, Monireh Hajimoradi, Neda Ghahremanzadeh, Seyed Hossein Razzaz, Safdar Masoomi, Maryam Taghdiri, Mohsen Bagheri, Mohsen Lofti, Akbar Khorasani, Masoud Ghader, Shiva Safari, Masumeh Shahsavn, Saeed Kalantari
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Vaccines
Subjects:
SARS-CoV-2
recombinant vaccine
immune response
immunogenicity
intranasal vaccine
Online Access:https://www.mdpi.com/2076-393X/11/2/455

Internet

https://www.mdpi.com/2076-393X/11/2/455

Similar Items